Cross-Sector entity
August Troendle is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is clinical-trial: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 2 original sources on average.
3 verified stories tracked
Last mentioned: 5d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
August Troendle is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is clinical-trial: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Johnson Financial Group Inc., all published on October 3, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johnson Financial Group Inc.. Shared-story counts are live from our verified record — not editorial picks.
Medpace Stock Declines 4.2%
MEDP shares traded down $26.10 to $598.08 on volume of 232,765 shares, below average.
CEO Sells 21,966 Shares
Troendle sold 21,966 shares at an average price of $625.47 for $13,739,074.02, reducing his position 6.10% to 338,225 shares.
Q2 Earnings Report
Medpace reported Q2 EPS of $4.25, revenue of $707.33 million, up 17.2% year over year, beating consensus estimates.
Medpace CEO August Troendle sold 24,376 shares for $15.2M across two late-September transactions, with MEDP dipping to $598.08. For health system and IT leaders tracking CRO capacity, insider selling adds a signal to watch alongside strong Q2 growth of 17.2%.
Medpace CEO August Troendle sold $15.23M in MEDP shares over two days, and the stock dropped 4.2% to $598.08. With a 35x PE and 2.78 PEG, investors must weigh strong Q2 earnings against insider selling near the stock's $677.90 high.
Two SEC filings reveal Medpace CEO August Troendle offloaded $15.2M in stock as the CRO trades near its 52-week high. For biopharma teams, Medpace's Q2 revenue growth of 17.2% and $707.3M revenue remain robust, but insider sales deserve attention amid rising trial outsourcing.
Source: themarketsdaily.com · tickerreport.com
